Hematopoietic Cell Transplantation (HCT) has significantly improved the survival of patients with lymphomas and plasma cell disorders (PCD). The safety and effectiveness of this procedure have improved over recent years. Named by ASCO in 2018 as the Advance of the Year, CAR T cell therapies are increasingly utilized in the management of lymphomas and PCD since the initial FDA approval in 2017 and are being given earlier in the course of disease, transforming the care of these diseases. Ongoing basic work promises to improve CAR T effectiveness and accessibility. This Research Topic describes the present role of CAR Ts, their impact on the role of HCT and the future of these 2 therapies in lymphomas and PCD.
The goal of this Research Topic is to provide basic background information on HCT and CAR T therapy, discuss their present roles in the management of lymphomas and PCD, focusing on recent progress, address practical technical issues as well as obstacles to broader use, and predict the future of these two modalities, based on current research. Numerous studies have demonstrated substantial deficits in the understanding by many practitioners of the appropriate role and timing of HCT. These shortcomings have led to underutilization and inappropriate timing of referral for transplantation. Given its very recent approval and growth, the need for understanding the basic work and practical aspects of CAR T therapy, including barriers to care, is even more pronounced. This issue will educate practitioners and others with transplantation and/or cellular therapy interest on basic background, best practice, and broad understanding of the power and limitations of these two therapies in lymphoma and PCD.
This Research Topic is devoted to the appropriate use of HCT and CAR T cell therapy in patients with lymphomas and PCD. The goal is to provide practitioners, researchers, and other interested individuals with a broad understanding of basic work, clinical progress, and practical issues with these important and transformational therapies, with emphasis on recent advances. Focused discussions will review the optimal use of each modality in specific disorders, toxicities of treatment, mechanisms of resistance, and novel targets for cellular therapy. Barriers to broader application of these therapies will be emphasized.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Hematopoietic Cell Transplantation (HCT) has significantly improved the survival of patients with lymphomas and plasma cell disorders (PCD). The safety and effectiveness of this procedure have improved over recent years. Named by ASCO in 2018 as the Advance of the Year, CAR T cell therapies are increasingly utilized in the management of lymphomas and PCD since the initial FDA approval in 2017 and are being given earlier in the course of disease, transforming the care of these diseases. Ongoing basic work promises to improve CAR T effectiveness and accessibility. This Research Topic describes the present role of CAR Ts, their impact on the role of HCT and the future of these 2 therapies in lymphomas and PCD.
The goal of this Research Topic is to provide basic background information on HCT and CAR T therapy, discuss their present roles in the management of lymphomas and PCD, focusing on recent progress, address practical technical issues as well as obstacles to broader use, and predict the future of these two modalities, based on current research. Numerous studies have demonstrated substantial deficits in the understanding by many practitioners of the appropriate role and timing of HCT. These shortcomings have led to underutilization and inappropriate timing of referral for transplantation. Given its very recent approval and growth, the need for understanding the basic work and practical aspects of CAR T therapy, including barriers to care, is even more pronounced. This issue will educate practitioners and others with transplantation and/or cellular therapy interest on basic background, best practice, and broad understanding of the power and limitations of these two therapies in lymphoma and PCD.
This Research Topic is devoted to the appropriate use of HCT and CAR T cell therapy in patients with lymphomas and PCD. The goal is to provide practitioners, researchers, and other interested individuals with a broad understanding of basic work, clinical progress, and practical issues with these important and transformational therapies, with emphasis on recent advances. Focused discussions will review the optimal use of each modality in specific disorders, toxicities of treatment, mechanisms of resistance, and novel targets for cellular therapy. Barriers to broader application of these therapies will be emphasized.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
